Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial

September 15, 2016 5:52 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Aerie Pharma (NASDAQ: AERI) is recently up $12.17 to $33.30 in the premarket after reporting 'successful' efficacy results of Phase 3 Roclatan trial. September call option implied volatility is at 190, October is at 200; compared to its 52-week range of 63 to 274.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment